Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.67
(-6.71%)
SEK 1.67
(-6.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -58.73 Million SEK | 43.45% |
| 2022 | -103.87 Million SEK | -61.88% |
| 2021 | -64.16 Million SEK | 55.11% |
| 2020 | -142.93 Million SEK | -282.96% |
| 2019 | -37.32 Million SEK | -121.75% |
| 2018 | -16.83 Million SEK | 60.05% |
| 2017 | -42.12 Million SEK | 35.6% |
| 2016 | -65.41 Million SEK | -7447.78% |
| 2015 | -866.61 Thousand SEK | 10.2% |
| 2014 | -965 Thousand SEK | -190.9% |
| 2013 | 1.06 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -58.27 Million SEK | 0.8% |
| 2023 Q4 | -58.73 Million SEK | 39.46% |
| 2023 Q3 | -97.02 Million SEK | -158.27% |
| 2023 FY | -58.73 Million SEK | 43.45% |
| 2023 Q1 | -65.86 Million SEK | 36.59% |
| 2023 Q2 | -37.56 Million SEK | 42.96% |
| 2022 Q1 | -59.02 Million SEK | 8.02% |
| 2022 Q4 | -103.87 Million SEK | 22.52% |
| 2022 Q2 | -34.61 Million SEK | 41.35% |
| 2022 FY | -103.87 Million SEK | -61.88% |
| 2022 Q3 | -134.06 Million SEK | -287.29% |
| 2021 FY | -64.16 Million SEK | 55.11% |
| 2021 Q2 | -115.8 Million SEK | 10.19% |
| 2021 Q3 | -106.3 Million SEK | 8.2% |
| 2021 Q1 | -128.94 Million SEK | 9.79% |
| 2021 Q4 | -64.16 Million SEK | 39.64% |
| 2020 Q2 | -159.37 Million SEK | -464.21% |
| 2020 FY | -142.93 Million SEK | -282.96% |
| 2020 Q4 | -142.93 Million SEK | 6.3% |
| 2020 Q3 | -152.53 Million SEK | 4.29% |
| 2020 Q1 | -28.24 Million SEK | 24.32% |
| 2019 Q4 | -37.32 Million SEK | 24.41% |
| 2019 FY | -37.32 Million SEK | -121.75% |
| 2019 Q1 | -68.2 Million SEK | -305.25% |
| 2019 Q2 | -56.11 Million SEK | 17.73% |
| 2019 Q3 | -49.37 Million SEK | 12.01% |
| 2018 Q2 | -31.26 Million SEK | 16.93% |
| 2018 FY | -16.83 Million SEK | 60.05% |
| 2018 Q4 | -16.83 Million SEK | 30.46% |
| 2018 Q3 | -24.2 Million SEK | 22.59% |
| 2018 Q1 | -37.64 Million SEK | 10.65% |
| 2017 FY | -42.12 Million SEK | 35.6% |
| 2017 Q1 | -60.89 Million SEK | 6.9% |
| 2017 Q4 | -42.12 Million SEK | 10.93% |
| 2017 Q3 | -47.29 Million SEK | 14.06% |
| 2017 Q2 | -55.04 Million SEK | 9.61% |
| 2016 Q4 | -65.41 Million SEK | 0.0% |
| 2016 Q1 | 867 Thousand SEK | 200.0% |
| 2016 FY | -65.41 Million SEK | -7447.78% |
| 2016 Q2 | -22.51 Million SEK | -2696.89% |
| 2015 Q1 | 1.04 Million SEK | 0.0% |
| 2015 Q4 | -867 Thousand SEK | 0.0% |
| 2015 Q3 | -867 Thousand SEK | 0.0% |
| 2015 FY | -866.61 Thousand SEK | 10.2% |
| 2014 FY | -965 Thousand SEK | -190.9% |
| 2013 FY | 1.06 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| NextCell Pharma AB | -46.79 Million SEK | -25.532% |
| Abliva AB (publ) | -57.24 Million SEK | -2.615% |
| Active Biotech AB (publ) | -33.2 Million SEK | -76.919% |
| Aptahem AB (publ) | 2.9 Million SEK | 2119.396% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -17.425% |
| BioInvent International AB (publ) | -236.3 Million SEK | 75.143% |
| BioArctic AB (publ) | -606.58 Million SEK | 90.317% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -49.147% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1187.722% |
| Cantargia AB (publ) | -139.74 Million SEK | 57.969% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -6263.705% |
| CombiGene AB (publ) | -101.44 Million SEK | 42.097% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 69.832% |
| Fluicell AB (publ) | -2.76 Million SEK | -2025.841% |
| Genovis AB (publ.) | -43.94 Million SEK | -33.672% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 143.603% |
| Mendus AB (publ) | -96.29 Million SEK | 39.002% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 28.546% |
| LIDDS AB (publ) | -13.51 Million SEK | -334.702% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 386.382% |
| Saniona AB (publ) | 40.44 Million SEK | 245.22% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -29.9% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -17.629% |
| Xintela AB (publ) | -7.8 Million SEK | -652.171% |
| Amniotics AB (publ) | -5.63 Million SEK | -942.915% |
| Corline Biomedical AB | -17.01 Million SEK | -245.268% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -99.902% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 82.15% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 29.86% |
| Intervacc AB (publ) | -88.16 Million SEK | 33.375% |
| Kancera AB (publ) | -45.69 Million SEK | -28.55% |
| Lipum AB (publ) | -8.46 Million SEK | -593.881% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -83.973% |
| Nanologica AB (publ) | -9.38 Million SEK | -525.66% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 82.394% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 135.367% |
| AcouSort AB (publ) | -23.98 Million SEK | -144.88% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 28.445% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -5.101% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 210.36% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -208.169% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 54.641% |
| Simris Alg AB (publ) | 85.07 Million SEK | 169.041% |
| Ziccum AB (publ) | -2.13 Million SEK | -2648.573% |
| SynAct Pharma AB | -61.75 Million SEK | 4.892% |
| OncoZenge AB (publ) | -12.62 Million SEK | -365.17% |
| Camurus AB (publ) | -1.16 Billion SEK | 94.96% |
| 2cureX AB (publ) | -13.4 Million SEK | -338.238% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2618.047% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 57.483% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -343.996% |
| I-Tech AB | -83.26 Million SEK | 29.455% |
| Cyxone AB (publ) | -16.67 Million SEK | -252.352% |
| Biosergen AB | -1.88 Million SEK | -3019.331% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -174.28% |
| Alzinova AB (publ) | -21.22 Million SEK | -176.722% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 12.228% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 29.859% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1033.718% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -182.484% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1876.346% |